Locked and loaded: Glythera signs antibodies & payloads for ADCs
Glythera has set out to develop candidate antibody-drug conjugates (ADCs) for difficult-to-treat cancers using components licensed in separate deals with Iontas and Cancer Research UK.
Glythera has set out to develop candidate antibody-drug conjugates (ADCs) for difficult-to-treat cancers using components licensed in separate deals with Iontas and Cancer Research UK.
Irvine Scientific has expanded its cell culture dry powder facility in California to support the projected increase of biotherapeutic production.
Campaigning group People for the Ethical Treatment of Animals (PETA) picketed a conference in Boston on Tuesday to protest the use of animals in drug research and development.